@article{MTMT:30434617,
	title = {Body-mass index correlates with severity and mortality in acute pancreatitis: A meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/30434617},
	author = {Dobszai, Dalma and Mátrai, Péter and Gyöngyi, Zoltán and Csupor, Dezső and Bajor, Judit and Erőss, Bálint Mihály and Mikó, Alexandra and Szakó, Lajos and Meczker, Ágnes and Hágendorn, Roland and Márta, Katalin and Szentesi, Andrea Ildikó and Hegyi, Péter},
	doi = {10.3748/wjg.v25.i6.729},
	journal-iso = {WORLD J LGASTROENTEROL},
	journal = {WORLD JOURNAL OF GASTROENTEROLOGY},
	volume = {25},
	unique-id = {30434617},
	issn = {1007-9327},
	year = {2019},
	eissn = {2219-2840},
	pages = {729-743},
	orcid-numbers = {Gyöngyi, Zoltán/0000-0001-9330-9119; Csupor, Dezső/0000-0002-4088-3333; Erőss, Bálint Mihály/0000-0003-3658-8427; Márta, Katalin/0000-0002-2213-4865; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:30636781,
	title = {Aging and Comorbidities in Acute Pancreatitis II.: A Cohort-Analysis of 1203 Prospectively Collected Cases},
	url = {https://m2.mtmt.hu/api/publication/30636781},
	author = {Szakács, Zsolt and Gede, Noémi and Pécsi, Dániel and Izbéki, Ferenc and Papp, Mária and Kovács, György and Fehér, Eszter and Dobszai, Dalma and Kui, Balázs and Márta, Katalin and Kónya, Klára and Szabó, Imre and Török, Imola and Gajdán, László and Takács, Tamás and Sarlós, Patrícia and Gódi, Szilárd and Varga, Márta and Hamvas, József and Vincze, Áron and Szentesi, Andrea Ildikó and Párniczky, Andrea and Hegyi, Péter},
	doi = {10.3389/fphys.2018.01776},
	journal-iso = {FRONT PHYSIOL},
	journal = {FRONTIERS IN PHYSIOLOGY},
	volume = {9},
	unique-id = {30636781},
	year = {2019},
	eissn = {1664-042X},
	orcid-numbers = {Szakács, Zsolt/0000-0002-7035-941X; Pécsi, Dániel/0000-0003-0499-6004; Izbéki, Ferenc/0000-0001-7767-4319; Papp, Mária/0000-0003-3662-4010; Márta, Katalin/0000-0002-2213-4865; Sarlós, Patrícia/0000-0002-5086-9455; Vincze, Áron/0000-0003-2217-7686; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:3422217,
	title = {The effect of serum triglyceride concentration on the outcome of acute pancreatitis : systematic review and meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/3422217},
	author = {Kiss, Lóránd and Fűr, Gabriella and Mátrai, Péter and Hegyi, Péter and Ivány, Emese and Cazacu, IM and Szabó, Imre and Habon, Tamás and Alizadeh, Hussain and Gyöngyi, Zoltán and Vigh, Éva and Erőss, Bálint Mihály and Erős, Adrienn and Ottoffy, M and Czakó, László and Rakonczay, Zoltán},
	doi = {10.1038/s41598-018-32337-x},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {8},
	unique-id = {3422217},
	issn = {2045-2322},
	abstract = {Elevated serum triglyceride concentration (seTG, >1.7 mM or >150 mg/dL) or in other words hypertriglyceridemia (HTG) is common in the populations of developed countries. This condition is accompanied by an increased risk for various diseases, such as acute pancreatitis (AP). It has been proposed that HTG could also worsen the course of AP. Therefore, in this meta-analysis, we aimed to compare the effects of various seTGs on the severity, mortality, local and systemic complications of AP, and on intensive care unit admission. 16 eligible studies, including 11,965 patients were retrieved from PubMed and Embase. The results showed that HTG significantly elevated the odds ratio (OR = 1.72) for severe AP when compared to patients with normal seTG (<1.7 mM). Furthermore, a significantly higher occurrence of pancreatic necrosis, persistent organ failure and renal failure was observed in groups with HTG. The rates of complications and mortality for AP were significantly increased in patients with seTG >5.6 mM or >11.3 mM versus <5.6 mM or <11.3 mM, respectively. We conclude that the presence of HTG worsens the course and outcome of AP, but we found no significant difference in AP severity based on the extent of HTG.},
	year = {2018},
	eissn = {2045-2322},
	orcid-numbers = {Hegyi, Péter/0000-0003-0399-7259; Habon, Tamás/0000-0002-4816-857X; Gyöngyi, Zoltán/0000-0001-9330-9119; Erőss, Bálint Mihály/0000-0003-3658-8427; Czakó, László/0000-0002-6331-0802; Rakonczay, Zoltán/0000-0002-1499-3416}
}

@article{MTMT:3407191,
	title = {Preexisting Diabetes Elevates Risk of Local and Systemic Complications in Acute Pancreatitis: Systematic Review and Meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/3407191},
	author = {Mikó, Alexandra and Borbásné Farkas, Kornélia and Garami, András and Szabó, Imre and Vincze, Áron and Veres, Gábor and Bajor, Judit and Alizadeh, Hussain and Rakonczay, Zoltán and Vigh, Éva and Márta, Katalin and Kiss, Z and Hegyi, Péter and Czakó, László},
	doi = {10.1097/MPA.0000000000001122},
	journal-iso = {PANCREAS},
	journal = {PANCREAS},
	volume = {47},
	unique-id = {3407191},
	issn = {0885-3177},
	abstract = {The prevalence of diabetes mellitus (DM) and acute pancreatitis (AP) increases continuously, therefore, to understand the effects of preexisting diabetes on AP is crucially needed. Here, we performed a systematic review and meta-analysis in which AP patients including DM and non-DM groups were sorted. Several outcome parameters were analyzed, and the odds ratio (OR) and standardized mean difference with 95% confidence intervals (CIs) were calculated.We found 1417 articles, of which 9 articles involving 354,880 patients were analyzed. More complications were seen in diabetic patients than in non-DM patients (OR, 1.553 [95% CI, 1.266-1.904]; P < 0.001). Intensive care unit admission (OR, 1.799 [95% CI, 1.442-2.243]; P < 0.001) and renal failure (OR, 1.585 [95% CI, 1.278-1.966]; P < 0.001) were more frequent in DM patients. There was a tendency of higher mortality and local complications (OR, 1.276 [95% CI, 0.991-1.643]; P = 0.059; and OR, 1.267 [95% CI, 0.964-1.659]; P = 0.090, respectively) in preexisting DM. Length of hospitalization was longer in DM patients (standardized mean difference, 0.217 [95% CI, 0.075-0.360]; P = 0.003). Preexisting DM negatively influences the outcome of AP and increases the risk of renal failure, local complications, and mortality.},
	keywords = {MELLITUS; COMPLICATIONS; MORTALITY; diabetes mellitus; IMPACT; Hospital Mortality; critical illness; POPULATION-BASED COHORT; L-arginine; OUTCOMES; Acute pancreatitis; CLINICAL-RELEVANCE; ANTIDIABETIC DRUGS},
	year = {2018},
	eissn = {1536-4828},
	pages = {917-923},
	orcid-numbers = {Borbásné Farkas, Kornélia/0000-0002-5349-6527; Garami, András/0000-0003-2493-0571; Vincze, Áron/0000-0003-2217-7686; Veres, Gábor/0000-0002-0911-1941; Rakonczay, Zoltán/0000-0002-1499-3416; Márta, Katalin/0000-0002-2213-4865; Hegyi, Péter/0000-0003-0399-7259; Czakó, László/0000-0002-6331-0802}
}

@article{MTMT:3267063,
	title = {High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial},
	url = {https://m2.mtmt.hu/api/publication/3267063},
	author = {Márta, Katalin and Szabó, Anikó Nóra and Pécsi, Dániel and Varjú, Péter and Bajor, Judit and Gódi, Szilárd and Sarlós, Patrícia and Mikó, Alexandra and Szemes, Kata and Papp, Mária and Tornai, Tamás and Vincze, Áron and Márton, Zsolt and Vincze, PA and Lanko, E and Szentesi, Andrea Ildikó and Molnar, T and Hágendorn, Roland and Faluhelyi, Nándor and Battyáni, István and Kelemen, Dezső and Papp, Róbert and Miseta, Attila János and Verzár, Zsófia and Lerch, MM and Neoptolemos, JP and Sahin-Tóth, Miklós and Petersen, OH and Hegyi, Péter},
	doi = {10.1136/bmjopen-2017-015874},
	journal-iso = {BMJ OPEN},
	journal = {BMJ OPEN},
	volume = {7},
	unique-id = {3267063},
	issn = {2044-6055},
	abstract = {INTRODUCTION: Acute pancreatitis (AP) is an inflammatory disease with no specific treatment. Mitochondrial injury followed by ATP depletion in both acinar and ductal cells is a recently discovered early event in its pathogenesis. Importantly, preclinical research has shown that intracellular ATP delivery restores the physiological function of the cells and protects from cell injury, suggesting that restoration of energy levels in the pancreas is therapeutically beneficial. Despite several high quality experimental observations in this area, no randomised trials have been conducted to date to address the requirements for energy intake in the early phase of AP. METHODS/DESIGN: This is a randomised controlled two-arm double-blind multicentre trial. Patients with AP will be randomly assigned to groups A (30 kcal/kg/day energy administration starting within 24 hours of hospital admission) or B (low energy administration during the first 72 hours of hospital admission). Energy will be delivered by nasoenteric tube feeding with additional intravenous glucose supplementation or total parenteral nutrition if necessary. A combination of multiorgan failure for more than 48 hours and mortality is defined as the primary endpoint, whereas several secondary endpoints such as length of hospitalisation or pain will be determined to elucidate more detailed differences between the groups. The general feasibility, safety and quality checks required for high quality evidence will be adhered to. ETHICS AND DISSEMINATION: The study has been approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (55961-2/2016/EKU). This study will provide evidence as to whether early high energy nutritional support is beneficial in the clinical management of AP. The results of this trial will be published in an open access way and disseminated among medical doctors. TRIAL REGISTRATION: The trial has been registered at the ISRCTN (ISRTCN 63827758).},
	year = {2017},
	eissn = {2044-6055},
	orcid-numbers = {Márta, Katalin/0000-0002-2213-4865; Pécsi, Dániel/0000-0003-0499-6004; Sarlós, Patrícia/0000-0002-5086-9455; Papp, Mária/0000-0003-3662-4010; Vincze, Áron/0000-0003-2217-7686; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Molnar, T/0000-0003-2571-3595; Miseta, Attila János/0000-0002-7984-3347; Verzár, Zsófia/0000-0001-5323-0748; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:2977076,
	title = {Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-Study Protocol of a Multinational Prospective Clinical Trial},
	url = {https://m2.mtmt.hu/api/publication/2977076},
	author = {Párniczky, Andrea and Mosztbacher, Dóra and Zsoldos, F and Tóth, Anna and Lasztity, N and Hegyi, Péter},
	doi = {10.1159/000441353},
	journal-iso = {DIGESTION},
	journal = {DIGESTION},
	volume = {93},
	unique-id = {2977076},
	issn = {0012-2823},
	abstract = {BACKGROUND: Single-centered studies show increased number of acute pancreatitis (AP) in children. Here, the Pediatric Section of the Hungarian Pancreatic Study Group introduces an international observational clinical trial (APPLE) to collect a critical mass of clinical data and biomedical research samples in a uniform prospective manner. SUMMARY: The APPLE-R is for patients under 18 years of age with a history of pancreatitis. The study primarily provides information on possible genetic variants behind the disease and their impact on the prognosis. The APPLE-P is for patients under 18 years of age with a diagnosis of AP. Children with AP diagnosed based on the fulfillment of '2 out of 3' of the Atlanta criteria will be selected. This subtrial requests detailed information from the medical history, etiology, complains and symptoms, physical examinations, laboratory parameters, imaging, immediate therapy at admission and complications of the disease. The APPLE trial has been registered at the ISRCTN registry and has received the relevant ethical approval. The study is open for all pediatric centers throughout the world. Key Message: This is the first worldwide study tracking earlier (APPLE-R) and ongoing episodes (APPLE-P) of pancreatitis.},
	year = {2016},
	eissn = {1421-9867},
	pages = {105-110},
	orcid-numbers = {Mosztbacher, Dóra/0000-0002-2446-9247; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:2980969,
	title = {Pain in the Early Phase of Pediatric Pancreatitis (PINEAPPLE Trial): Pre-Study Protocol of a Multinational Prospective Clinical Trial},
	url = {https://m2.mtmt.hu/api/publication/2980969},
	author = {Zsoldos, F and Párniczky, Andrea and Mosztbacher, Dóra and Tóth, Anna and Lasztity, N and Hegyi, Péter},
	doi = {10.1159/000441352},
	journal-iso = {DIGESTION},
	journal = {DIGESTION},
	volume = {93},
	unique-id = {2980969},
	issn = {0012-2823},
	abstract = {BACKGROUND: There are unexpectedly large differences between the incidences of acute pancreatitis (AP) as indicated by different hospitals. Retrospective studies suggest that the reason behind this is the large differences that exist between the local managements of abdominal pain at emergency units. Unfortunately, no evidence-based medicine (EBM) guidelines are available to give proper instruction concerning the necessity of serum pancreatic enzyme measurement during abdominal pain. SUMMARY: Pain in Early Phase of Pediatric Pancreatitis (PINEAPPLE) is an observational, multinational observational clinical trial to explore the route from the first sign of abdominal pain to the diagnosis of pancreatitis (PINEAPPLE trial). The PINEAPPLE-R subtrial is a retrospective review on the records of children (patients under 18) appearing at emergency units - a review of their clinical symptoms, results of imaging examinations and laboratory parameters. The PINEAPPLE-P subtrial is a prospective trial designed to develop a fast and simple EBM guideline that helps to evaluate (in a reliable and cost-efficient way) the necessity of pancreatic enzyme test and abdominal ultrasonography (or even computed tomography) when a child has abdominal pain. The trial has been registered at the ISRCTN registry and has received the relevant ethical approval. Key Message: The PINEAPPLE trial will help to recognize AP in children in a highly efficient manner.},
	year = {2016},
	eissn = {1421-9867},
	pages = {121-126},
	orcid-numbers = {Mosztbacher, Dóra/0000-0002-2446-9247; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:2861419,
	title = {Preventive pancreatic stents in the management of acute biliary pancreatitis (PREPAST trial): Pre-study protocol for a multicenter, prospective, randomized, interventional, controlled trial},
	url = {https://m2.mtmt.hu/api/publication/2861419},
	author = {Dubravcsik, Zsolt and Madácsy, László and Gyökeres, Tibor Zoltán and Vincze, Áron and Szepes, Zoltán and Hegyi, Péter and Hritz, István and Szepes, A},
	doi = {10.1016/j.pan.2015.02.007},
	journal-iso = {PANCREATOLOGY},
	journal = {PANCREATOLOGY},
	volume = {15},
	unique-id = {2861419},
	issn = {1424-3903},
	abstract = {BACKGROUND: The outcome of the most common biliary form of acute pancreatitis has not changed even with the better described indications for early endoscopic intervention. It may be due to the fact that this intrevention theoretically can cause further pancreatic injury or cannot always relieve the pancreatic duct obstruction. We hypothesize that maintaining the outflow of the pancreatic duct with preventive pancreatic stents at the early ERCP improves the outcome of acute biliary pancreatitis. METHODS/DESIGN: PREPAST is a prospective, randomized, controlled, multicenter trial. Patients with acute biliary pancreatitis with coexisting cholangitis are randomized to undergo urgent endoscopic intervention with or without pancreatic stenting within 48 h from the onset of pain, and in addition patients without signs of cholangitis but cholestasis are randomly allocated to recieve conservative treatment or early endoscopic intervention with or without pancreatic stenting within 48 h from the onset of pain. Patients without acute cholangitis and signs of cholestasis recieve conservative treatment. 230 patients are planned to be enrolled during a 48 months period from different centers. The primary endpoint is the outcome of acute biliary pancreatitis as described by the latest guidelines. Secondary endpoints include mortality data, and other variables not analyzed as a primary endpoint but related to the pancreatitis or the pancreatic stenting. DISCUSSION: The PREPAST trial is designed to show whether early endoscopic intervention with the usage of preventive pancreatic stenting improves the outcome of acute biliary pancreatitis. The study has been registered at the International Standard Randomised Controlled Trial Number (ISRCTN) Register (trial ID: ISRCTN13517695).},
	year = {2015},
	eissn = {1424-3911},
	pages = {115-123},
	orcid-numbers = {Dubravcsik, Zsolt/0000-0002-7231-3300; Vincze, Áron/0000-0003-2217-7686; Szepes, Zoltán/0000-0002-9466-8719; Hegyi, Péter/0000-0003-0399-7259; Hritz, István/0000-0002-8763-6006}
}

@article{MTMT:2913239,
	title = {Early Achievable Severity (EASY) index for simple and accurate expedite risk stratification in acute pancreatitis.},
	url = {https://m2.mtmt.hu/api/publication/2913239},
	author = {Hritz, István and Hegyi, Péter},
	doi = {10.15403/jgld.2014.1121.242.easy},
	journal-iso = {J GASTROINTEST LIVER},
	journal = {JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES},
	volume = {24},
	unique-id = {2913239},
	issn = {1841-8724},
	abstract = {BACKGROUND: Acute pancreatitis (AP) is one of the most common diseases of the gastrointestinal tract associated with significant morbidity and mortality. The assessment of severity is crucial in the management of the disease. Current methods of risk stratification in AP have a limited value, as they provide little additional information thus delaying appropriate patient care. Early recognition of severe disease may prevent serious adverse events and improve patient management as well as overall clinical outcome. METHODS/DESIGN: The EASY trial is an observational, multicenter, prospective cohort study for establishing a simple, easy and accurate clinical scoring system for early prognostication of AP. Evaluation of simple attainable potential prognostic parameters obtained at admission (or not later than 6-12 hours afterwards) from patients diagnosed with AP will be performed to assess their potential correlation with the disease severity. The selected parameters that show the strongest correlation with severe disease course will be further utilized as potential early severity prognostic markers for prospective new patient stratification. Comparison of patients' clinical course with the obtained results of early risk stratification may validate the utilized parameters as prognostic markers. The trial has been (i) discussed and (ii) accepted in a distinguished international scientific meeting, (ii) receiving the relevant ethical approval (TUKEB: 30595-1/2014/EKU), (ii) registered at the ISRCTN registry which is a primary clinical trial registry recognized by WHO (Trial registration number: ISRCTN10525246). CONCLUSION: The EASY trial is designed to develop a simple and accurate clinical scoring system that can stratify patients with AP during the first 6-12 hours of hospitalization according to their risk for severe disease course.},
	year = {2015},
	eissn = {1842-1121},
	pages = {177-182},
	orcid-numbers = {Hritz, István/0000-0002-8763-6006; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:2987981,
	title = {IAP/APA evidence-based guidelines for the management of acute pancreatitis},
	url = {https://m2.mtmt.hu/api/publication/2987981},
	author = {Marc, Besselink and Hjalmar, van Santvoort and Martin, Freeman and Timothy, Gardner and Julia, Mayerle and Santhi, Swaroop Vege and Jens, Werner and Peter, Banks and Colin, McKay and Carlos, Fernandez-del Castillo and Jeremy, French and Hein, Gooszen and Colin, Johnson and Mike, Sarr and Tadahiro, Takada and John, Windsor and Ashok, Saluja and Rodger, Liddle and Georgios, Papachristou and Vijay, Singh and Michael, Rünzi and Vikesh, Singh and Peter, Banks and Thomas, Bollen and Desiree, Morgan and Koenraad, Mortele and Anubhav, Mittal and Mao, En-qiang and Timothy, Gardner and Jan, de Waele and Maxim, Petrov and Patchen, Dellinger and Marc, Besselink and Markus, M. Lerch and Roland, Anderson and Stephen, McClave and Werner, Hartwig and Hjalmar, van Santvoort and Martin, Freeman and Marco, Bruno and Alejandro, Oria and Peter, Banks and Hein, Gooszen and Todd, Baron and Carlos, Fernandez-del Castillo and Peter, Fagenholz and Karen, Horvath and Koenraad, Mortele and Mark, van Baal and William, Nealon and Ake, Andren-Sandberg and Olaf, Bakker and Claudio, Bassi and Markus, Buchler and Marja, Boermeester and Ed, Bradley and Suresh, Chari and Richard, Charnley and Saxon, Connor and Christos, Dervenis and Jacques, Deviere and Vikas, Dudeja and Paul, Fockens and Chris, Forsmark and Helmut, Friess and Shuji, Isaji and Rainer, Isenmann and Ernst, Klar and Philippe, Lévy and Keith, Lillemoe and Xubao, Liu and Chengdu, Matthias Löhr and Toshihiko, Mayumi and Joachim, Mossner and John, Neoptolemos and Isto, Nordback and Oláh, Attila and Roy, Padbury and Rowan, Parks and Dejan, Radenkovic and Bettina, Rau and Vinciane, Rebours and Stefan, Seewald and Hans, Seifert and Tooru, Shimosegawa and Ajith, Siriwardena and William, Steinberg and Robert, Sutton and Masao, Tanaka and Kazunori, Takeda and Francis, Tse and Harry, van Goor and Andrew, Warshaw and Chunyou, Wang and David, Whitcomb and Yupei, Zhao and Nicholas, Zyromski},
	doi = {10.1016/j.pan.2013.07.063},
	journal-iso = {PANCREATOLOGY},
	journal = {PANCREATOLOGY},
	volume = {13},
	unique-id = {2987981},
	issn = {1424-3903},
	year = {2013},
	eissn = {1424-3911},
	pages = {1-15}
}

@article{MTMT:1244823,
	title = {Interactions between the endocrine and exocrine pancreas and their clinical relevance},
	url = {https://m2.mtmt.hu/api/publication/1244823},
	author = {Czakó, László and Hegyi, Péter and Rakonczay, Zoltán and Wittmann, Tibor and Otsuki, M},
	doi = {10.1159/000181169},
	journal-iso = {PANCREATOLOGY},
	journal = {PANCREATOLOGY},
	volume = {9},
	unique-id = {1244823},
	issn = {1424-3903},
	abstract = {In consequence of the close anatomical and functional links between the exocrine 
		and endocrine pancreas, any disease affecting one of these parts will inevitably 
		affect the other. Pancreatic conditions which might cause diabetes mellitus
		include acute and chronic pancreatitis, pancreatic surgery, cystic fibrosis and
		pancreatic cancer. The development of diabetes greatly influences the prognosis
		and quality of life of patients with exocrine pancreatic diseases. It may cause
		life-threatening complications, such as hypoglycemia, due to the lack of glucagon
		and the impaired absorption of nutrients, or the micro- and macrovascular
		complications may impair the organ functions. Diabetes mellitus is an independent
		risk factor of mortality in those with exocrine pancreatic diseases. The
		treatment of pancreatic diabetes, a distinct metabolic and clinical form of
		diabetes, requires special knowledge. Diet and pancreatic enzyme replacement
		therapy may be sufficient in the early stages. Oral antidiabetic drugs are not
		recommended. If the diet proves inadequate to reach the glycemic goals, insulin
		treatment with multiple injections is required. Impairments of the exocrine
		pancreatic function and morphology in diabetic patients are frequent and well
		known. Atrophy of the exocrine tissue may be caused by the lack of trophic
		insulin, whereas pancreatic fibrosis can result from activation of stellate cells
		by hyperglycemia, or from microangiopathy and neuropathy. The regulation of the
		exocrine pancreatic function is also damaged because of the impaired effect of
		islet hormones. In the event of a proven impairment of the pancreatic exocrine
		function in diabetes mellitus, pancreatic enzyme replacement therapy is
		indicated. This may improve the nutritional condition of the patient and decrease
		the metabolic instability. and IAP.},
	year = {2009},
	eissn = {1424-3911},
	pages = {351-359},
	orcid-numbers = {Czakó, László/0000-0002-6331-0802; Hegyi, Péter/0000-0003-0399-7259; Rakonczay, Zoltán/0000-0002-1499-3416}
}

@article{MTMT:1073461,
	title = {Cholecystokinin fails to promote pancreatic regeneration in diabetic rats following the induction of experimental pancreatitis},
	url = {https://m2.mtmt.hu/api/publication/1073461},
	author = {Takács, Tamás and Hegyi, Péter and Pintér Olivérné Jármay, Katalin and Czakó, László and Góg, C and Rakonczay, Zoltán and Németh, J and Lonovics, János},
	doi = {10.1006/phrs.2001.0843},
	journal-iso = {PHARMACOL RES},
	journal = {PHARMACOLOGICAL RESEARCH},
	volume = {44},
	unique-id = {1073461},
	issn = {1043-6618},
	abstract = {The aim of the present study was to investigate the spontaneous and cholecystokinin-octapeptide (CCK-8)-promoted laboratory changes and morphological alterations in rats with arginine (Arg)induced pancreatitis in which diabetes had been induced with streptozotocin (STZ). Male Wistar rats were used in our experiments. Pancreatitis was induced by arginine, diabetes by STZ and regeneration was promoted by CCK-8. The serum amylase, glucose and insulin levels, the pancreatic contents of protein, DNA, amylase, trypsinogen and lipase, the pancreatic weight/body-weight ratio (pw/bw) and the plasma glucagon level were examined 1, 3, 7, 14 and 28 days after pancreatitis induction. Pancreatic tissue samples were examined by light microscopy and immunostaining on paraffin-embedded sections. The insulin and glucagon-containing cells were visualized by using monoclonal antibodies. The administration of low doses of CCK-8 accelerated the processes of regeneration following Arg-induced pancreatitis, but in rats that were also diabetic, pancreatic regeneration was not observed. The administration of low doses of CCK-8 seems to reduce the pancreatic beta -cell number and function in diabetic rats. The pancreatic endocrine function was further deteriorated by simultaneous Arg-induced pancreatitis. The diabetic state appeared to shift the normal pancreatic enzyme content (decreased amylase and increased trypsinogen) in this study.},
	year = {2001},
	eissn = {1096-1186},
	pages = {363-372},
	orcid-numbers = {Hegyi, Péter/0000-0003-0399-7259; Czakó, László/0000-0002-6331-0802; Rakonczay, Zoltán/0000-0002-1499-3416}
}

@article{MTMT:1073045,
	title = {Spontaneous and cholecystokinin-octapeptide-promoted regeneration of the pancreas following L-arginine-induced pancreatitis in rat},
	url = {https://m2.mtmt.hu/api/publication/1073045},
	author = {Hegyi, Péter and Takács, Tamás and Pintér Olivérné Jármay, Katalin and Nagy, I and Czakó, László and Lonovics, János},
	doi = {10.1007/BF02788384},
	journal-iso = {INT J PANCREATOL},
	journal = {INTERNATIONAL JOURNAL OF PANCREATOLOGY},
	volume = {22},
	unique-id = {1073045},
	issn = {0169-4197},
	abstract = {Conclusion. In L-arginine (Arg)-induced pancreatitis, evidence of acute inflammation was observed on d 1-3. Continuous tissue atrophy became visible at the sites of previous pancreatic necrosis, with simultaneous regeneration of the pancreas, mainly around the Langerhans islets, Administration of low doses of cholecystokinin-octapeptide (CCK-8) increased the inflammatory signs of pancreatitis in the early phase, but subsequently diminished the level of atrophy and accelerated the processes of regeneration in this model of pancreatitis.
		
		Background. The aim of this work was to study the regenerative processes following Arg-induced pancreatitis in rats. Besides the spontaneous regeneration, the effects of low doses of CCK-8 on the laboratory and morphologic parameters in this type of experimental pancreatitis were investigated.
		
		Methods. Male Wistar rats were divided into three groups. In group I, the rats received 200 mg/100 g body weight of Arg ip twice, at an interval of 1 h, and 0.5 mt saline was administered sc twice daily. In group II, besides the same amount of Arg, the rats received 1 mu g/kg of CCK-8 sc in 0.5-mL saline twice daily (7 AM and 7 PM). In the control animals (group III), an identical amount of glycine was administered ip instead of Arg at the same times. The rats were examined on d 1, 3, 7, 14, and 28 after pancreatitis induction. The pancreatic weight/body weight ratio (pw/bw) was calculated in each case. The serum levels of amylase, and glucose and the pancreatic contents of soluble protein, trypsin, amylase and DNA were determined, and histologic examinations were performed.
		
		Results. In groups I and II, both pw/bw (3.5 +/- 0.2 mg/g and 4.1 +/- 0.28 mg/g, respectively) and the serum amylase level (8900 +/- 560 IU/L and 11100 +/- 1390 IU/L, respectively) were significantly elevated on d 1 vs group III (2.1 +/- 0.06 mg/g and 5562 +/- 373 IU/L, respectively). Pw/bw was significantly decreased in groups I (0.96 +/- 0.12 mg/g, 0.8 +/- 0.1 mg/g, and 1.8 +/- 0.1 mg/g, respectively) and II (1.4 +/- 0.15 mg/g, 1.7 +/- 0.2 mg/g, and 1.95 +/- 0.1 mg/g, respectively) on d 7, 14, and 28 vs group III (2.6 +/- 0.3 mg/g, 3.1 +/- 0.15 mg/g, and 2.7 +/- 0.1 mg/g, respectively), whereas in group II it was significantly elevated vs. group I on d 7 and 14. The pancreatic contents of soluble protein, DNA, trypsin and amylase were significantly decreased on d 3-14 in groups I and II vs group III. The pancreatic DNA level was significantly elevated in group LT (1.23 +/- 0.2 mg/pancreas) vs group I (0.7 +/- 0.1 mg/pancreas) on d 7. In group II, the soluble protein (73.1 +/- 15.5 mg/pancreas) and amylase (1104 +/- 160 IU/pancreas) levels were significantly elevated on d 14 as was that of trypsin (27.2 +/- 3.1 IU/pancreas) on d 28, vs group I (26.4 +/- 5.3 mg/p, 525 +/- 111 IU/pancreas, and 16.3 +/- 1.1 IU/pancreas, respectively). On histologic sections, the signs of acute inflammation of the pancreas were more pronounced in group II than in group I on d 1-3. After that lime, in spite of the progressive atrophy of the pancreas, the signs of tis sue repair were more expressed in group II.},
	year = {1997},
	pages = {193-200},
	orcid-numbers = {Hegyi, Péter/0000-0003-0399-7259; Czakó, László/0000-0002-6331-0802}
}